Efficacy and safety of valsartan in children aged 1-5 years with hypertension, with or without chronic kidney disease: A 6-week randomised, multicentre, double-blind study followed by open-label phase
31 August 2019 (00:00 - 00:00)
Organised by:
About the speaker
Novartis, Hyderabad (India)
14 More presentations in this session
Doctor R. Hmazzou (Paris, FR)
Doctor C. Helten (Duesseldorf, DE)
Doctor F. Chacon-Lozsan (Budapest, HU)
Doctor C. Paterno Marchioli (Castiglion Fiorentino (AR), IT)
Access the full session
The Event
ESC Congress 2019
31 August - 4 September 2019
You may be interested in
Congress Presentation
Congress Session
